University of Tokyo Edge Capital joined a second close that expanded the cell therapy developer's series B round by an extra $11m.
Nohla Therapeutics, a US-based cell therapy spinout from Fred Hutchinson Cancer Research Center, has reached the $56m second close of a series B round featuring University of Tokyo Edge Capital.
University of Tokyo Edge Capital, an investment vehicle for the institution, participated in the second close alongside Schroder Adveq and Premier Partners.
Nohla raised an initial $45m tranche in May this year backed by pharmaceutical firm Celgene, life sciences real estate developer Alexandria Real Estate Equities and financial services group…